A multicenter randomized phase II/III trial of preoperative versus postoperative chemotherapy with XELOX plus bevacizumab in patients with resectable colorectal liver metastasis.
Active, no longer recruiting
Phase of Trial: Phase II/III
Latest Information Update: 04 Jun 2018
At a glance
- Drugs Capecitabine (Primary) ; Oxaliplatin (Primary) ; Bevacizumab
- Indications Adenocarcinoma; Liver metastases
- Focus Therapeutic Use
- Acronyms HiSCO-01
- 27 May 2018 Planned End Date changed from 1 Jun 2018 to 31 May 2028.
- 27 May 2018 Status changed from recruiting to active, no longer recruiting.
- 10 May 2012 New trial record